Optimizing the Cas13 antiviral train: cargo and delivery
Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2023-05-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.202217146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849235091441582080 |
|---|---|
| author | Shruti Sharma Cameron Myhrvold |
| author_facet | Shruti Sharma Cameron Myhrvold |
| author_sort | Shruti Sharma |
| collection | DOAJ |
| description | Abstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13‐based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves. |
| format | Article |
| id | doaj-art-7c3b25f2b6074bb8bceff30221f02e44 |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2023-05-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-7c3b25f2b6074bb8bceff30221f02e442025-08-20T04:02:55ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842023-05-011571210.15252/emmm.202217146Optimizing the Cas13 antiviral train: cargo and deliveryShruti Sharma0Cameron Myhrvold1Department of Electrical and Computer Engineering, Princeton UniversityDepartment of Molecular Biology, Princeton UniversityAbstract The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic in 2020 highlighted the need for rapid, widespread responses against infectious disease. One such innovation uses CRISPR‐Cas13 technology to directly target and cleave viral RNA, thereby inhibiting replication. Due to their programmability, Cas13‐based antiviral therapies can be rapidly deployed to target emerging viruses, in comparison with traditional therapeutic development that takes at least 12–18 months, and often many years. Moreover, similar to the programmability of mRNA vaccines, Cas13 antivirals can be developed to target mutations as the virus evolves.https://doi.org/10.15252/emmm.202217146 |
| spellingShingle | Shruti Sharma Cameron Myhrvold Optimizing the Cas13 antiviral train: cargo and delivery EMBO Molecular Medicine |
| title | Optimizing the Cas13 antiviral train: cargo and delivery |
| title_full | Optimizing the Cas13 antiviral train: cargo and delivery |
| title_fullStr | Optimizing the Cas13 antiviral train: cargo and delivery |
| title_full_unstemmed | Optimizing the Cas13 antiviral train: cargo and delivery |
| title_short | Optimizing the Cas13 antiviral train: cargo and delivery |
| title_sort | optimizing the cas13 antiviral train cargo and delivery |
| url | https://doi.org/10.15252/emmm.202217146 |
| work_keys_str_mv | AT shrutisharma optimizingthecas13antiviraltraincargoanddelivery AT cameronmyhrvold optimizingthecas13antiviraltraincargoanddelivery |